While breast cancers that are hormone receptor positive (HR+) at diagnosis are associated with a more favourable prognosis than those that are hormone receptor negative (HR-), the incidence of recurrence after 5 years is significantly higher for HR + tumours (Zhang et al., 2013). This evidence concerns the gene NR4A1 and breast cancer.